Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-27T14:32:54.592Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and Safety of Varenicline to Treat Nicotine Dependence in a Smokers Population with High Prevalence of Psychiatric Comorbidities

Published online by Cambridge University Press:  15 April 2020

L. Trofor ,
R. Gherghesanu ,
R. Chirita ,
I.O. Pascal ,
R. Miron ,
A.C. Trofor  and
A. Frunza
L. Trofor
Affiliation:
Psychiatry I, University of Medicine and Pharmacy “Gr.T.Popa”, Iasi, Romania
R. Gherghesanu
Affiliation:
Psychiatry I, Clinic of Psychiatric Diseases, Iasi, Romania
R. Chirita
Affiliation:
Psychiatry I, Clinic of Psychiatric Diseases, Iasi, Romania
I.O. Pascal
Affiliation:
Psychiatry I, University of Medicine and Pharmacy “Gr.T.Popa”, Iasi, Romania
R. Miron
Affiliation:
Pneumology I, Clinic of Pulmonary Diseases, Iasi, Romania
A.C. Trofor
Affiliation:
Pneumology I, Clinic of Pulmonary Diseases, Iasi, Romania
A. Frunza
Affiliation:
Bioengineering, University of Medicine and Pharmacy “Gr.T.Popa”, Iasi, Romania

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Smokers with psychiatric comorbidities are prevalent in our current practice. Varenicline (Champix) is a first line pharmacotherapy indicated to treat nicotine addiction.

Aim

To assess efficacy and safety of varenicline in current practice of a smoking cessation center treating smokers with high prevalence of psychiatric disorders.

Material and method

128 smokers with concurrent stable psychiatric, respiratory or cardiovascular disorders (study group) and 124 healthy smokers (control group) were treated with varenicline and counseling, for 12 weeks to stop smoking. Abstinence rate was assessed in both groups at 12 weeks. Varenicline safety, cessation profile and compliance to treatment were monitored in psychiatric disorders smokers compared to other co-morbidities and to controls.

Results

54.6 % smokers with comorbidities (12/22 cardiovascular, 14/30 respiratory, 44/76 psychiatric) and 33.8 % healthy smokers successfully quit smoking. Withdrawal symptoms and adverse effects picture did not differ significantly between groups. The figure shows compliance to treatment and number of adverse events in healthy and psychiatric, respiratory and cardiovascular disease smokers.

 Compliance to treatment (%)Adverse effects (n)
 2 weeks4 weeks8 weeks12 weeks 
Healthy smokers (n=124)80.680.677.472.511
Smokers with psychiatric disorders (n=76)97.394.786.886.814
Smokers with respiratory disorders (n=30)83.37056.6408
Smokers with cardiovascular disorders (n=22)10072.759598

Conclusions

Smokers with psychiatric co-morbidities achieved a higher abstinence rate, compared to respiratory and cardiovascular disease smokers and to control group. Varenicline proved comparable safety in both study and control groups.<a name="_GoBack"></a>

Type
Article: 0473
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.